Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated Primary Liver Cancer

NCT05292443 WITHDRAWN

To evaluate the predictive value of ctDNA in response, relapse for liver cancer patients treated with immune checkpoint inhibitors

Details

Lead sponsor	Geneplus-Beijing Co. Ltd.
Status	WITHDRAWN
Start date	Mon Dec 20 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Mar 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Primary Liver Cancer
• Hepatocellular Carcinoma
• Intrahepatic Cholangiocarcinoma
• Combined Hepatocellular-cholangiocarcinoma

Interventions

• Observation

Countries

China